Obuprazine Schizophrenia Clinical Trial: Phase 2b Data
Obuprazine (TRTL-107) beat placebo at all three doses in a 363-patient Phase 2b trial in China. Key PANSS results, safety gaps and next steps.
FDA Approves Teva’s Weltruza: The First Once-Monthly Subcutaneous Olanzapine for Schizophrenia
FDA approved Teva’s Weltruza (olanzapine monthly injection) on October 9, 2026—the first once-monthly subcutaneous olanzapine for schizophrenia. SOLARIS trial: PANSS -11.27 pts. No loading dose, no monitoring required.
Once-Monthly Olanzapine Injection: 1st FDA Approval Revealed
The once-monthly olanzapine injection Weltruza gets FDA approval for adults with schizophrenia. Doses, SOLARIS data, safety and launch timing.